Salvage extracorporeal membrane oxygenation in induction-associated acute respiratory distress syndrome in acute leukemia patients: A case series

The International Journal of Artificial Organs
Nikhil A HuprikarPhillip E Mason

Abstract

The prognosis of hematologic malignancies has improved over the past three decades. However, the prognosis in hematologic malignancies with severe acute respiratory distress syndrome has remained poor. Initial reports regarding the utility of extracorporeal membrane oxygenation in hematologic malignancies have been controversial, with limited evaluations of acute leukemia patients supported by extracorporeal membrane oxygenation. We conducted a retrospective review of patients with acute leukemia who developed acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation support at our facility from July 2015 through August 2017. Four cases of acute myelogenous leukemia with respiratory failure and acute respiratory distress syndrome treated with veno-venous extracorporeal membrane oxygenation while undergoing induction chemotherapy were identified. All patients completed induction therapy with addition of extracorporeal membrane oxygenation support, with two patients dying secondary to their acute leukemia and the other two surviving to allogeneic hematopoietic stem cell transplant. Overall, 75% (three of four) survived to decannulation with a 1-year survival rate following extracorporeal membra...Continue Reading

References

Apr 24, 2012·Journal of Critical Care·Kiran ShekarJason A Roberts
Jan 22, 2014·Critical Care : the Official Journal of the Critical Care Forum·Philipp WohlfarthUNKNOWN Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine In
Jan 31, 2014·Leukemia & Lymphoma·Anne-Sophie MoreauElie Azoulay
Jun 6, 2014·Intensive Care Medicine·Elie AzoulayMichael Darmon
Jan 18, 2015·Transfusion Medicine Reviews·Deirdre A MurphyAmanda K Davis
May 23, 2015·Blood Reviews·Elie AzoulayUNKNOWN Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique (Grrr-OH)
Jul 15, 2015·The Korean Journal of Internal Medicine·Hye Seon KangJong Wook Lee
Aug 15, 2015·Intensive Care Medicine·Matthieu SchmidtAlain Combes
Jul 23, 2016·Canadian Respiratory Journal : Journal of the Canadian Thoracic Society·Alan P KraguljacSangeeta Mehta
Apr 15, 2017·Critical Care Medicine·Philipp WohlfarthUNKNOWN Caring for Critically Ill Immunocompromised Patients Multinational Network (NINE-I)
Sep 28, 2017·Current Opinion in Critical Care·Mitchell H RosnerMark A Perazella

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
flow cytometry

Software Mentioned

SAMMC

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.